PT-CD16VS

N/A

Report date: 2024/11/20 16:40:06

Base Information

Drug NamePT-CD16VS

Drug Alias NamePT-CD16VS

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulatorsLow affinity immunoglobulin gamma Fc region receptor III agonists

TargetsReceptor protein-tyrosine kinase erbB-2Low affinity immunoglobulin gamma Fc region receptor III

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCelularity Inc

China Registration ClassN/A

Develop Information

Active CompaniesCelularity Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A